Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Licenses Rights to MicroRNA Sequences from Max Planck

NEW YORK (GenomeWeb News) - Stratagene said today that it has licensed rights to more than 150 microRNA sequences from Max Planck Innovation, the commercial arm of the Max Planck Society.
Under the agreement, Stratagene purchased co-exclusive rights to use the sequences to make and sell molecular diagnostic kits based on its FullVelocity platform.
The company said it is particularly interested in the use of microRNAs for cancer biomarker applications.
Max Planck Innovation said that over the past five years it has generated more than €100 million ($130 million) through technology transfer licenses.